Polarean Imaging PLC Directorate Change (6569B)
03 Febrero 2020 - 1:01AM
UK Regulatory
TIDMPOLX
RNS Number : 6569B
Polarean Imaging PLC
03 February 2020
Polarean Imaging Plc
("Polarean" or the "Company")
Directorate Change
Jonathan Allis, Ph.D. assumes Chairman role
Polarean Imaging plc (AIM: POLX), a clinical stage medical
imaging technology company developing a proprietary magnetic
resonance imaging (MRI) drug-device combination, announces that
Jonathan Allis, Non-Executive Director, has assumed the role of
Chairman with immediate effect. Dr. Allis has a wealth of direct
knowledge in healthcare and the medical imaging contrast agent
industry and is currently the Founder and Chief Executive Officer
of Blue Earth Diagnostics ("Blue Earth"), which was recently
acquired by Bracco Imaging for US$450 million.
Jonathan Allis' appointment follows the resignations of both
Richard Morgan the Company's Non - Executive Chairman and Robert
Bertoldi, Non - Executive Director, from the Company's Board of
Directors with immediate effect (the "Resignations").
The Company has also commenced the search for a new Non -
Executive Director and will make a further announcement in due
course.
Both Mr. Morgan and Mr. Bertoldi hold options over 534,400
ordinary shares in the capital of the Company ( "Options"). As per
the Company's announcement of 20 April 2018, these Options vest in
equal portions on an annual basis on 29 March, being the
anniversary of the Company's Admission to trading on AIM and expire
on 29 March 2028. Following the Resignations all of the Options
will vest and any unexercised Options will lapse on 31 December
2020.
Richard Hullihen, Chief Executive Officer of Polarean said: "The
Board would like to sincerely thank Richard and Bob for their
guidance and service during the intense process of the Company's
formation, launch and early stage development. Their leadership was
invaluable in listing, the fundraising process and the successful
completion of the Company's Phase III clinical trials. We wish them
well in their future endeavours.
"The Company welcomes Jonathan Allis stepping up to Chairman
ahead of the next phase of Polarean's lifecycle as we move toward
regulatory submission and proposed commercial launch. Prior to
founding Blue Earth, Jonathan was the General Manager for PET at GE
Healthcare Life Sciences and in previous roles with GE, was
responsible for their hyperpolarised Xenon business, which is now
owned by Polarean."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contacts:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
SP Angel Corporate Finance LLP Nomad Tel: +44 (0)20 3470 0470
and Broker
David Hignell / Soltan Tagiev (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
741 001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical drug-device
combination companies operating in the high-resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specializes in the use of hyperpolarized Xenon gas ((129) Xe) as an
imaging agent to visualize ventilation.(129) Xe gas is currently
being studied for visualization of gas exchange regionally in the
smallest airways of the lungs, the tissue barrier between the lung,
and the bloodstream and in the pulmonary vasculature. Xenon gas
exhibits solubility and signal properties that enable it to be
imaged within other tissues and organs.
The Group also develops and manufactures high performance MRI
radiofrequency (RF) coils which are a required component for
imaging (129) Xe in the MRI system. The development of these coils
by the Group facilitates the adoption of the Xenon technology by
providing application-specific RF coils which optimize the imaging
of (129) Xe in MRI equipment for use as a medical diagnostic as
well as a method of monitoring the efficacy of therapeutic
intervention.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUPUMPPUPUGUP
(END) Dow Jones Newswires
February 03, 2020 02:01 ET (07:01 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024